糖尿病治療薬市場：製品、用途、流通チャネル別-2025-2030年の世界予測

糖尿病治療薬市場の2023年の市場規模は691億2,000万米ドルで、2024年には729億7,000万米ドルに達すると予測され、CAGR 5.88％で成長し、2030年には1,031億8,000万米ドルに達すると予測されています。

糖尿病治療薬市場には、1型糖尿病、2型糖尿病、妊娠糖尿病を含む糖尿病患者の血糖値改善を目的とした医薬品が含まれます。この市場は、座りがちなライフスタイル、不健康な食生活、高齢化などの要因により世界的に糖尿病の有病率が上昇していることから、ますます重要性を増しています。糖尿病治療薬の中核用途と最終用途範囲には、急性および長期合併症のリスクを軽減し、患者の生活の質を向上させるための血糖値管理が含まれます。市場の洞察によると、主な成長要因としては、薬剤製剤の継続的な進歩、糖尿病管理に関する意識の高まり、ヘルスケアインフラへの多額の投資などが挙げられます。さらに、新興国における糖尿病罹患率の増加は、市場拡大の潜在的な機会をもたらしています。最新のビジネスチャンスは、個別化医療や包括的な糖尿病管理ソリューションを提供するデジタルツールの開発に見出すことができます。しかし、市場成長を阻む課題には、厳しい規制の枠組み、糖尿病治療薬に伴う副作用、低所得地域でのアクセスを制限する可能性のある先進治療薬の高コストなどがあります。技術革新が期待される分野には、スマートインスリンペンのようなドラッグデリバリーシステムの強化、治療成果を高めるための糖尿病管理における人工知能の統合などがあります。さらに、SGLT2阻害薬やGLP-1受容体作動薬などの新規治療薬クラスの開発が、市場の展望を形成し続けています。また、製薬企業とハイテク企業のコラボレーションにより、より革新的な統合ソリューションの創出が促進される可能性があることも注目に値します。要するに、市場はダイナミックで可能性に満ちており、技術の進歩と、より効率的で利用しやすい糖尿病治療ソリューションへのニーズの高まりがその原動力となっています。しかし、こうした機会を捉えるには規制やコストの障壁を克服する必要があり、事業成長を推進するための研究開発への戦略的投資の重要性が強調されています。

市場力学：急速に進化する糖尿病治療薬市場の主要市場インサイトを公開

糖尿病治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の糖尿病有病率の増加
  • 糖尿病に対する政府の取り組みと支援的な保健政策
  • 先進製剤の研究開発の活発化
• 市場抑制要因
  • 糖尿病治療薬の高コストと糖尿病管理の複雑さ
• 市場機会
  • 研究所と製薬企業間の協力関係の構築
  • 個別化医療に対する消費者の需要の高まり
• 市場の課題
  • 政府の厳しい承認手続き

ポーターの5つの力：糖尿病治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：糖尿病治療薬市場における外部からの影響の把握

外部マクロ環境要因は、糖尿病治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析糖尿病治療薬市場における競合情勢の把握

糖尿病治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス糖尿病治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、糖尿病治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨糖尿病治療薬市場における成功への道筋を描く

糖尿病治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に糖尿病の罹患率が増加
    • 糖尿病に対する政府の取り組みと支援的な健康政策
    • 先進的な医薬品製剤の研究開発活動の拡大
  • 抑制要因
    • 糖尿病治療薬の高コストと糖尿病管理の複雑さ
  • 機会
    • 調査室と製薬会社間の新たな連携
    • 消費者の間でパーソナライズ医療の需要が高まる
  • 課題
    • 厳格な政府承認手続き
• 市場セグメンテーション分析
  • 製品：消費者の間で持続性インスリン薬の需要が高まっている
  • 用途：2型糖尿病の治療への応用が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 糖尿病治療薬市場：製品別

• インスリン
  • 中間型インスリン
  • 持続性インスリン
  • 混合インスリン
  • 速効型インスリン
  • 速効型インスリン
• インスリン以外の注射薬
  • アミリン類似体
  • GLP-1受容体作動薬
• 経口薬
  • ビグアナイド
  • DPP-4阻害剤
  • SGLT-2阻害剤
  • スルホニル尿素
  • チアゾリジンジオン

第7章 糖尿病治療薬市場：用途別

• 妊娠糖尿病
• 1型糖尿病
• 2型糖尿病

第8章 糖尿病治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカの糖尿病治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の糖尿病治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの糖尿病治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • イーライリリー、中国で糖尿病治療薬ティルゼパタイドの承認を取得
  • サノフィ・インドは、治療の簡素化とコンプライアンスの向上を目指し、2型糖尿病と肥満症の治療薬「ソリクア」を発売しました。
  • ルピンはジェネリック糖尿病薬の米国FDA承認を取得し、競争力のある価格設定と戦略的拡大で年間500万米ドルの米国市場を狙う
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Astellas Pharma Inc.
• AstraZeneca PLC
• Baxter International, Inc.
• Bayer AG
• Biocon Limited
• Bioton S.A.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Eva Pharma
• GlaxoSmithKline PLC
• Glenmark Pharmaceuticals Limited
• Gulf Pharmaceutical Industries（Julphar）
• Johnson & Johnson Services, Inc.
• Lupin Limited
• MannKind Corporation
• Merck & Co., Inc.
• MJ Biopharm Pvt. Ltd.
• Novartis AG
• Novo Nordisk A/S
• Oramed Pharmaceuticals Inc.
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Tonghua Dongbao Pharmaceutical Co., Ltd.
• Viatris Inc.
• Zydus Lifesciences Limited

LIST OF FIGURES

• FIGURE 1. DIABETES DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. DIABETES DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DIABETES DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DIABETES DRUGS MARKET SIZE, BY RAPID-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DIABETES DRUGS MARKET SIZE, BY SGLT-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DIABETES DRUGS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. CANADA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. CANADA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 55. CANADA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 56. CANADA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 57. CANADA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. CANADA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. CHINA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. CHINA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 87. CHINA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 88. CHINA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 89. CHINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. CHINA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. INDIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. INDIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 93. INDIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 94. INDIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 95. INDIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. INDIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. ITALY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 195. ITALY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 196. ITALY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 197. ITALY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 198. ITALY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 199. ITALY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 218. POLAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 219. POLAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 220. POLAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 221. POLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 222. POLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 223. POLAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 224. QATAR DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 225. QATAR DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 226. QATAR DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 227. QATAR DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 228. QATAR DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 229. QATAR DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 284. DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 285. DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Diabetes Drugs Market was valued at USD 69.12 billion in 2023, expected to reach USD 72.97 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 103.18 billion by 2030.

The diabetes drugs market encompasses pharmaceuticals aiming to improve blood sugar levels in individuals with diabetes, including type 1, type 2, and gestational diabetes. This market has become increasingly crucial as the prevalence of diabetes globally is rising due to factors like sedentary lifestyles, unhealthy diets, and aging populations. The core applications and end-use scope of diabetes drugs involve managing blood glucose levels to mitigate the risk of acute and long-term complications, improving the quality of life for patients. Market insights reveal that key growth influencers include the continuous advancements in drug formulation, increasing awareness about diabetes management, and substantial investments in healthcare infrastructure. Moreover, the increasing incidence of diabetes in emerging economies presents potential opportunities for market expansion. Latest opportunities can be found in the development of personalized medicine and digital tools that offer comprehensive diabetes management solutions. However, limitations challenging market growth include stringent regulatory frameworks, side effects associated with diabetes medication, and the high cost of advanced therapeutic drugs, which may limit access in low-income regions. Areas poised for innovation include enhancing drug delivery systems, such as smart insulin pens, and the integration of artificial intelligence in diabetes management to enhance therapeutic outcomes. Furthermore, the development of novel therapeutic classes, including SGLT2 inhibitors and GLP-1 receptor agonists, continues to shape the market landscape. It's also noteworthy that collaboration between pharmaceutical companies and tech firms could facilitate the creation of more innovative, integrated solutions. In essence, the market is dynamic and ripe with potential, driven by technological advances and a growing need for more efficacious and accessible diabetic care solutions. However, capturing these opportunities necessitates overcoming regulatory and cost barriers, emphasizing the importance of strategic investment in research and development to propel business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetes Drugs Market

The Diabetes Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of diabetes globally
  • Government Initiatives and supportive health policies for diabetes
  • Growing research and development activities for advanced drug formulations
• Market Restraints
  • High cost of diabetes medications and complexity of diabetes management
• Market Opportunities
  • Emerging collaborations among research labs and pharmaceutical companies
  • Rising demand for personalized medicine among consumers
• Market Challenges
  • Stringent government approval procedures

Porter's Five Forces: A Strategic Tool for Navigating the Diabetes Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetes Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetes Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetes Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetes Drugs Market

A detailed market share analysis in the Diabetes Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetes Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetes Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetes Drugs Market

A strategic analysis of the Diabetes Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetes Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Baxter International, Inc., Bayer AG, Biocon Limited, Bioton S.A., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Eva Pharma, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Gulf Pharmaceutical Industries (Julphar), Johnson & Johnson Services, Inc., Lupin Limited, MannKind Corporation, Merck & Co., Inc., MJ Biopharm Pvt. Ltd., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Tonghua Dongbao Pharmaceutical Co., Ltd., Viatris Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Diabetes Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Insulin, Non-Insulin Injectable Drugs, and Oral Drug. The Insulin is further studied across Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin, Rapid-Acting Insulin, and Short-Acting Insulin. The Non-Insulin Injectable Drugs is further studied across Amylin Analogs and GLP-1 Receptor Agonists. The Oral Drug is further studied across Biguanides, DPP-4 inhibitors, SGLT-2 inhibitors, Sulfonylureas, and Thiazolidinediones.
• Based on Application, market is studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of diabetes globally
    • 5.1.1.2. Government Initiatives and supportive health policies for diabetes
    • 5.1.1.3. Growing research and development activities for advanced drug formulations
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of diabetes medications and complexity of diabetes management
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging collaborations among research labs and pharmaceutical companies
    • 5.1.3.2. Rising demand for personalized medicine among consumers
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent government approval procedures
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Rising demand for long-acting insulin drugs among consumers
  • 5.2.2. Application: Increasing application for treatment of type 2 diabetes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Diabetes Drugs Market, by Product

• 6.1. Introduction
• 6.2. Insulin
  • 6.2.1. Intermediate-Acting Insulin
  • 6.2.2. Long-Acting Insulin
  • 6.2.3. Premixed Insulin
  • 6.2.4. Rapid-Acting Insulin
  • 6.2.5. Short-Acting Insulin
• 6.3. Non-Insulin Injectable Drugs
  • 6.3.1. Amylin Analogs
  • 6.3.2. GLP-1 Receptor Agonists
• 6.4. Oral Drug
  • 6.4.1. Biguanides
  • 6.4.2. DPP-4 inhibitors
  • 6.4.3. SGLT-2 inhibitors
  • 6.4.4. Sulfonylureas
  • 6.4.5. Thiazolidinediones

7. Diabetes Drugs Market, by Application

• 7.1. Introduction
• 7.2. Gestational Diabetes
• 7.3. Type 1 Diabetes
• 7.4. Type 2 Diabetes

8. Diabetes Drugs Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Diabetes Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Diabetes Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Diabetes Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Eli Lilly gains approval for diabetes drug Tirzepatide in China
  • 12.3.2. Sanofi India launches Soliqua for Type 2 diabetes and obesity, aiming to simplify treatment and improve compliance
  • 12.3.3. Lupin secures USFDA approval for a generic diabetes drug, targets USD 5 million annual US market with competitive pricing and strategic expansion
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Astellas Pharma Inc.
• 3. AstraZeneca PLC
• 4. Baxter International, Inc.
• 5. Bayer AG
• 6. Biocon Limited
• 7. Bioton S.A.
• 8. Boehringer Ingelheim International GmbH
• 9. Bristol-Myers Squibb Company
• 10. Eli Lilly and Company
• 11. Eva Pharma
• 12. GlaxoSmithKline PLC
• 13. Glenmark Pharmaceuticals Limited
• 14. Gulf Pharmaceutical Industries (Julphar)
• 15. Johnson & Johnson Services, Inc.
• 16. Lupin Limited
• 17. MannKind Corporation
• 18. Merck & Co., Inc.
• 19. MJ Biopharm Pvt. Ltd.
• 20. Novartis AG
• 21. Novo Nordisk A/S
• 22. Oramed Pharmaceuticals Inc.
• 23. Pfizer Inc.
• 24. Sanofi S.A.
• 25. Takeda Pharmaceutical Company Limited
• 26. Tonghua Dongbao Pharmaceutical Co., Ltd.
• 27. Viatris Inc.
• 28. Zydus Lifesciences Limited